Can-Fite BioPharma Ltd. (CANF)

IL — Healthcare Sector

Peers: ICCC CGEN EVGN CLGN PLX CRVS ALDX GMDA CKPT CADL BRTX XTLB CING ADIL RNAZ ADTX RVPH ATXI BVXV ORMP MDWD BLRX

Automate Your Wheel Strategy on CANF

With Tiblio's Option Bot, you can configure your own wheel strategy including CANF - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

symbol CANF
Rev/Share 0.0003
Book/Share 0.0021
PB 1.6839
Debt/Equity 0.0191
CurrentRatio 4.3772
ROIC -1.1417

MktCap 13971761.0
FreeCF/Share -0.003
PFCF -1.8283
PE -1.1619
Debt/Assets 0.0114
DivYield 0
ROE -1.9907

Rating C
Score 2
Recommendation Sell
P/E Score 1
DCF Score 1
P/B Score 2
D/E Score 4

Recent Analyst Ratings

Type	Ticker	Analyst Firm	Previous Rating	Current Rating	Previous Price Target	Current Price Target	Date
No ratings available.

News

Can-Fite Announces $3.0 Million Registered Direct Offering of American Depositary Shares

CANF
Published: April 14, 2025 by: GlobeNewsWire
Sentiment: Neutral

RAMAT GAN, Israel, April 14, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small-molecule drugs for oncological and inflammatory diseases (“Can-Fite” or the “Company”), today announced that it has entered into definitive agreements for the purchase and sale of 2,500,000 of the Company's American Depositary Shares (“ADSs”), at a purchase price of $1.20 per ADS, in a registered direct offering. The offering is expected to close on or about April 15, 2025, subject to satisfaction of customary closing conditions.

image for news Can-Fite Announces $3.0 Million Registered Direct Offering of American Depositary Shares

Can-Fite Partner Vetbiolix Accelerate Piclidenoson Development with Advanced Clinical Trial for Canine Osteoarthritis in a $3.8 Billion Market

CANF
Published: March 20, 2025 by: GlobeNewsWire
Sentiment: Neutral

Can-Fite's upfront and royalties on sales upon regulatory approval of Piclidenoson for veterinary use, is projected to be $325 million in the aggregate over the next decade assuming a 2029 launch

image for news Can-Fite Partner Vetbiolix Accelerate Piclidenoson Development with Advanced Clinical Trial for Canine Osteoarthritis in a $3.8 Billion Market

Can-Fite to Initiate Phase II Study in the Rare Genetic Disease Lowe Syndrome with Piclidenoson

CANF
Published: March 19, 2025 by: GlobeNewsWire
Sentiment: Neutral

FDA & EMA approvals for rare genetic diseases are fast and require clinical studies with small number of patients

image for news Can-Fite to Initiate Phase II Study in the Rare Genetic Disease Lowe Syndrome with Piclidenoson

About Can-Fite BioPharma Ltd. (CANF)

IPO Date 2012-11-06
Website https://www.canfite.com
Industry Biotechnology
CEO Mr. Motti Farbstein
Employees 5

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19. It also develops Namodenoson that is in Phase III clinical trial for the treatment of hepatocellular carcinoma, as well as in Phase IIb trial for the treatment of non-alcoholic steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. Can-Fite BioPharma Ltd. has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and collaboration agreement with Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. Can-Fite BioPharma Ltd. was incorporated in 1994 and is headquartered in Petah Tikva, Israel.